Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1563880 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $18.09Day −1.84%Mkt cap $2.6B1Y +139.6%Off 52W high −10.5%Vol (1Y) 63.9%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,812 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest8.9% of sh out |
| Days to cover4.8d |
| 13F net flow (QoQ)+1.51% |
| Top-10 13F concentration50.2% |
| Next report (est.)2026-08-04 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Earnings (TTM)-$45.6M |
| ROE−30.2% |
| ROIC−33.9% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+44.5% |
| 1Y+139.6% |
| 3Y+660.1% |
| 5Y+847.1% |
| Since incept. (ann.)+12.2% |
Total return through 2026-07-29 · series begins 2019-05-07. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)63.9% |
| Ann. volatility (3Y)74.9% |
| Sharpe (1Y)1.70 |
| Sharpe (3Y)1.29 |
| Max drawdown (1Y)−29.5% |
| Max drawdown (3Y)−56.9% |
| Beta (3Y vs SPY)−0.12 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| NEA Management Company, LLC | 13.2M | $158M | 9.31% | +0.0% |
| BlackRock, Inc. | 10.2M | $122M | 7.21% | +1.1% |
| Frazier Life Sciences Management, L.P. | 9.9M | $119M | 7.00% | −3.1% |
| FMR LLC | 8.0M | $96M | 5.66% | +23.7% |
| WELLINGTON MANAGEMENT GROUP LLP | 5.2M | $62M | 3.65% | +52.4% |
| Vivo Capital, LLC | 5.1M | $61M | 3.59% | +0.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.0M | $59M | 3.51% | new |
| MARSHALL WACE, LLP | 4.0M | $47M | 2.79% | −13.4% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-05 | −$0.09 | — | — | — |
| 2025-09-30 | 2025-11-13 | −$0.08 | — | — | — |
| 2025-06-30 | 2025-08-07 | −$0.09 | — | — | — |
| 2025-03-31 | 2025-05-08 | −$0.09 | — | — | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-04 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
